HemaXis Micro Blood Sampling
  • HOME
  • PRODUCTS
    • HEMAXIS DB
      Whole Blood Collection
    • HEMAXIS DX
      Plasma/Serum Collection
    • DOCUMENTATION
      Instructions, App Notes, Articles
  • APPLICATIONS
    • OVERVIEW
    • PEth TESTING
    • IMMUNOSUPPRESSANT MONITORING
    • DRUG OF ABUSE
    • IN-COMPETITION DRUG TESTING
    • COVID-19 SEROLOGY TESTING
    • WORKPLACE COVID-19 Serology testing
  • COMPANY
    • ABOUT US
    • NEWSROOM
  • TRY HEMAXIS
  • Menu

La révolution de la prise de sang est en marche

July 9, 2015/in News /by hemaxisdbs

Share this entry
  • Share on Facebook
  • Share on Twitter
  • Share on Linkedin
  • Share by Mail
https://hemaxis.com/wp-content/uploads/2015/03/news-lacote-logo.jpg 303 797 hemaxisdbs http://hemaxis.com/wp-content/uploads/2016/08/hemaxis-logo-x1.png hemaxisdbs2015-07-09 05:53:162020-01-31 14:27:29La révolution de la prise de sang est en marche

Recent Posts

  • COVID-19 Serology Workplace Testing
  • HemaXis is contributing in clinical trial to better understand COVID-19
  • Are blood tests possible without seeing a doctor?
  • World Anti-Doping Agency developing Dried Blood Spot testing
  • Volume controlled Dried Blood Spot (DBS): A key player in personalized medicine
  • Cansford Laboratories turns to HemaXis DB 10 for sampling in their PEth testing program
  • Zaragoza University uses HemaXis for Hg quantification
  • HemaXis DB 10 available at Cibesmed
  • HemaXis DB 10 application presented in the German Symposium
  • Joining Lyonbiopôle
  • HemaXis™ DB10 samples professional cyclists in drug monitoring program
  • DBS System’s HemaXis™ DB 10 blood collection device is now CE/IVD marked
  • Efficient Alcohol Consumption Monitoring
  • HemaXis DB launched in the U.S. with FDA listing
  • USPTO Patent Granted For HemaXis Microfluidic Blood Collection Platform

DISCLAIMER

HemaXis DB is a FDA Class 1 medical device. HemaXis DX is in development and for research purposes only. Use of HemaXis devices in Laboratory Developed Tests (LDTs) requires further processing including the establishment of performance characteristics and successful validation by the laboratory in a manner consistent with local regulatory requirements.

By using this website you are agreeing to our Terms and Conditions.

CONTACT

DBS System SA
Rte des Avouillons 6
CH-1196 Gland
Switzerland

Tel: +41 (0) 78 624 70 15
Email: info@dbs-system.ch

LEGAL DOCUMENTS

Read Our Privacy Policy
Read Our General Terms and Conditions of Sale
Read Our Shipping Information

CONNECT WITH US

Linkedin

Twitter

YouTube

Newsletter

© Copyright - Hemaxis 2018 All rights reserved | The Webb Agency
Scroll to top